Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-61.11%)
USD 0.0
(-61.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.29 Million USD | 48.25% |
| 2022 | -39.2 Million USD | 42.03% |
| 2021 | -67.63 Million USD | -107.69% |
| 2020 | -32.56 Million USD | -18.53% |
| 2019 | -27.47 Million USD | -33.81% |
| 2018 | -20.53 Million USD | -11.31% |
| 2017 | -18.44 Million USD | 53.29% |
| 2016 | -39.49 Million USD | 28.42% |
| 2015 | -55.17 Million USD | -25.22% |
| 2014 | -44.05 Million USD | 2.56% |
| 2013 | -45.21 Million USD | -21.17% |
| 2012 | -37.31 Million USD | -77.99% |
| 2011 | -20.96 Million USD | -9.34% |
| 2010 | -19.17 Million USD | 36.59% |
| 2009 | -30.24 Million USD | 22.67% |
| 2008 | -39.1 Million USD | 2.25% |
| 2007 | -40 Million USD | 13.66% |
| 2006 | -46.33 Million USD | 21.34% |
| 2005 | -58.9 Million USD | -27.49% |
| 2004 | -46.2 Million USD | -90.29% |
| 2003 | -24.28 Million USD | -39.2% |
| 2002 | -17.44 Million USD | -56.5% |
| 2001 | -11.14 Million USD | -2.62% |
| 2000 | -10.86 Million USD | -119.06% |
| 1999 | -4.95 Million USD | 68.22% |
| 1998 | -15.6 Million USD | -69.57% |
| 1997 | -9.2 Million USD | -300.0% |
| 1996 | -2.3 Million USD | 17.86% |
| 1995 | -2.8 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -12.02 Million USD | -217.66% |
| 2024 Q1 | 10.21 Million USD | 298.27% |
| 2023 Q2 | -6.6 Million USD | -60.57% |
| 2023 Q4 | -5.15 Million USD | -16.47% |
| 2023 FY | -20.29 Million USD | 48.25% |
| 2023 Q3 | -4.42 Million USD | 32.96% |
| 2023 Q1 | -4.11 Million USD | 57.58% |
| 2022 FY | -39.2 Million USD | 42.03% |
| 2022 Q1 | -8.12 Million USD | 37.83% |
| 2022 Q2 | -17.33 Million USD | -113.28% |
| 2022 Q3 | -4.05 Million USD | 76.6% |
| 2022 Q4 | -9.69 Million USD | -138.95% |
| 2021 Q3 | -8.21 Million USD | 78.03% |
| 2021 Q2 | -37.38 Million USD | -317.24% |
| 2021 Q1 | -8.96 Million USD | -20.22% |
| 2021 FY | -67.63 Million USD | -107.69% |
| 2021 Q4 | -13.07 Million USD | -59.17% |
| 2020 Q4 | -7.45 Million USD | 17.36% |
| 2020 Q1 | -6.53 Million USD | 11.4% |
| 2020 Q2 | -9.55 Million USD | -46.28% |
| 2020 FY | -32.56 Million USD | -18.53% |
| 2020 Q3 | -9.02 Million USD | 5.63% |
| 2019 FY | -27.47 Million USD | -33.81% |
| 2019 Q4 | -7.37 Million USD | -3.49% |
| 2019 Q3 | -7.12 Million USD | -10.7% |
| 2019 Q2 | -6.43 Million USD | 1.53% |
| 2019 Q1 | -6.53 Million USD | 27.7% |
| 2018 Q3 | -3.92 Million USD | -28.67% |
| 2018 FY | -20.53 Million USD | -11.31% |
| 2018 Q1 | -4.51 Million USD | -282.45% |
| 2018 Q2 | -3.05 Million USD | 32.36% |
| 2018 Q4 | -9.04 Million USD | -130.25% |
| 2017 Q1 | -8.72 Million USD | -32.14% |
| 2017 Q2 | -6.75 Million USD | 22.6% |
| 2017 Q4 | 2.47 Million USD | 145.43% |
| 2017 Q3 | -5.44 Million USD | 19.39% |
| 2017 FY | -18.44 Million USD | 53.29% |
| 2016 FY | -39.49 Million USD | 28.42% |
| 2016 Q4 | -6.6 Million USD | 21.06% |
| 2016 Q1 | -13.9 Million USD | -37.51% |
| 2016 Q3 | -8.36 Million USD | 21.28% |
| 2016 Q2 | -10.62 Million USD | 23.57% |
| 2015 Q1 | -12.17 Million USD | -14.52% |
| 2015 Q3 | -21.55 Million USD | -90.32% |
| 2015 Q2 | -11.32 Million USD | 7.0% |
| 2015 Q4 | -10.1 Million USD | 53.1% |
| 2015 FY | -55.17 Million USD | -25.22% |
| 2014 Q4 | -10.63 Million USD | 6.08% |
| 2014 Q1 | -11.47 Million USD | 2.16% |
| 2014 Q3 | -11.32 Million USD | -6.6% |
| 2014 Q2 | -10.62 Million USD | 7.43% |
| 2014 FY | -44.05 Million USD | 2.56% |
| 2013 Q2 | -8.62 Million USD | 31.72% |
| 2013 Q4 | -11.72 Million USD | 4.05% |
| 2013 Q3 | -12.22 Million USD | -41.69% |
| 2013 Q1 | -12.63 Million USD | -85.4% |
| 2013 FY | -45.21 Million USD | -21.17% |
| 2012 Q3 | -13.34 Million USD | -86.97% |
| 2012 Q4 | -6.81 Million USD | 48.94% |
| 2012 Q2 | -7.13 Million USD | 28.73% |
| 2012 FY | -37.31 Million USD | -77.99% |
| 2012 Q1 | -10.01 Million USD | -132.88% |
| 2011 Q2 | -8.07 Million USD | -110.48% |
| 2011 Q4 | -4.3 Million USD | 9.47% |
| 2011 FY | -20.96 Million USD | -9.34% |
| 2011 Q3 | -4.75 Million USD | 41.17% |
| 2011 Q1 | -3.83 Million USD | 33.15% |
| 2010 FY | -19.17 Million USD | 36.59% |
| 2010 Q1 | -7.28 Million USD | -18.68% |
| 2010 Q2 | -6.31 Million USD | 13.39% |
| 2010 Q4 | -5.74 Million USD | 12.82% |
| 2010 Q3 | -6.58 Million USD | -4.31% |
| 2009 Q1 | -9 Million USD | -5.41% |
| 2009 Q3 | -7.19 Million USD | 9.07% |
| 2009 FY | -30.24 Million USD | 22.67% |
| 2009 Q2 | -7.9 Million USD | 12.13% |
| 2009 Q4 | -6.14 Million USD | 14.6% |
| 2008 FY | -39.1 Million USD | 2.25% |
| 2008 Q3 | -10.63 Million USD | -4.15% |
| 2008 Q4 | -8.53 Million USD | 19.75% |
| 2008 Q2 | -10.21 Million USD | -5.16% |
| 2008 Q1 | -9.71 Million USD | 18.81% |
| 2007 Q3 | -9.34 Million USD | 9.99% |
| 2007 Q2 | -10.38 Million USD | -24.96% |
| 2007 Q1 | -8.31 Million USD | -5.93% |
| 2007 FY | -40 Million USD | 13.66% |
| 2007 Q4 | -11.96 Million USD | -28.0% |
| 2006 Q3 | -7.99 Million USD | 45.57% |
| 2006 FY | -46.33 Million USD | 21.34% |
| 2006 Q4 | -7.84 Million USD | 1.91% |
| 2006 Q1 | -15.79 Million USD | 46.19% |
| 2006 Q2 | -14.69 Million USD | 6.96% |
| 2005 FY | -58.9 Million USD | -27.49% |
| 2005 Q2 | -9.82 Million USD | -5.47% |
| 2005 Q1 | -9.31 Million USD | 53.54% |
| 2005 Q3 | -10.4 Million USD | -5.9% |
| 2005 Q4 | -29.35 Million USD | -182.11% |
| 2004 Q2 | -8.89 Million USD | -0.28% |
| 2004 Q4 | -20.05 Million USD | -139.23% |
| 2004 Q3 | -8.38 Million USD | 5.79% |
| 2004 FY | -46.2 Million USD | -90.29% |
| 2004 Q1 | -8.87 Million USD | -1.9% |
| 2003 FY | -24.28 Million USD | -39.2% |
| 2003 Q3 | -6.21 Million USD | -28.25% |
| 2003 Q2 | -4.84 Million USD | -7.64% |
| 2003 Q1 | -4.5 Million USD | 14.3% |
| 2003 Q4 | -8.7 Million USD | -40.01% |
| 2002 Q2 | -4.28 Million USD | -27.21% |
| 2002 Q1 | -3.37 Million USD | 19.99% |
| 2002 Q3 | -4.52 Million USD | -5.64% |
| 2002 Q4 | -5.25 Million USD | -16.07% |
| 2002 FY | -17.44 Million USD | -56.5% |
| 2001 Q1 | -2.06 Million USD | 49.2% |
| 2001 Q4 | -4.21 Million USD | -67.21% |
| 2001 FY | -11.14 Million USD | -2.62% |
| 2001 Q3 | -2.51 Million USD | -6.96% |
| 2001 Q2 | -2.35 Million USD | -14.32% |
| 2000 Q4 | -4.05 Million USD | -75.92% |
| 2000 Q3 | -2.3 Million USD | -3.92% |
| 2000 Q2 | -2.21 Million USD | -50.88% |
| 2000 Q1 | -1.47 Million USD | -38.94% |
| 2000 FY | -10.86 Million USD | -119.06% |
| 1999 Q1 | -2 Million USD | -25.0% |
| 1999 Q4 | -1.05 Million USD | -51.14% |
| 1999 Q3 | -700 Thousand USD | 36.36% |
| 1999 FY | -4.95 Million USD | 68.22% |
| 1999 Q2 | -1.1 Million USD | 45.0% |
| 1998 Q4 | -1.6 Million USD | -33.33% |
| 1998 Q3 | -1.2 Million USD | 88.68% |
| 1998 Q2 | -10.6 Million USD | -381.82% |
| 1998 Q1 | -2.2 Million USD | 71.43% |
| 1998 FY | -15.6 Million USD | -69.57% |
| 1997 Q2 | -500 Thousand USD | 16.67% |
| 1997 Q1 | -600 Thousand USD | 14.29% |
| 1997 Q3 | -300 Thousand USD | 40.0% |
| 1997 FY | -9.2 Million USD | -300.0% |
| 1997 Q4 | -7.7 Million USD | -2466.67% |
| 1996 Q4 | -700 Thousand USD | 12.5% |
| 1996 Q3 | -800 Thousand USD | -100.0% |
| 1996 Q2 | -400 Thousand USD | 0.0% |
| 1996 FY | -2.3 Million USD | 17.86% |
| 1996 Q1 | -400 Thousand USD | 33.33% |
| 1995 Q4 | -600 Thousand USD | 14.29% |
| 1995 Q2 | -1.1 Million USD | -175.0% |
| 1995 FY | -2.8 Million USD | 0.0% |
| 1995 Q3 | -700 Thousand USD | 36.36% |
| 1995 Q1 | -400 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1419.435% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -190.584% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 138.3% |
| Nascent Biotech, Inc. | -2.08 Million USD | -871.939% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1889.314% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 131.153% |
| Qrons Inc. | -789.34 Thousand USD | -2470.606% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3108.535% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 67.586% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4783.761% |
| Skye Bioscience, Inc. | -37.64 Million USD | 46.099% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 72.932% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -208.556% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -7321.672% |
| SQZ Biotechnologies Company | -79.46 Million USD | 74.465% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -601.53% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1014.567% |
| Mesoblast Limited | -87.95 Million USD | 76.931% |
| Marizyme, Inc. | -65.34 Million USD | 68.949% |
| Genus plc | 7.9 Million USD | 356.848% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -86.297% |
| Pharming Group N.V. | -10.54 Million USD | -92.368% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -835.149% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -446.893% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -129.432% |
| ContraFect Corporation | -65.15 Million USD | 68.856% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -315.283% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -1074.618% |
| IMV Inc. | -36.48 Million USD | 44.386% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -151.759% |
| MultiCell Technologies, Inc. | -380.07 USD | -5338653.388% |
| ONE Bio Corp. | 8.67 Million USD | 333.859% |
| Accustem Sciences Inc. | -3.74 Million USD | -441.611% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 60.746% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -1501.33% |
| Q BioMed Inc. | -2.05 Million USD | -888.795% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -443.557% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -752.251% |
| Biomind Labs Inc. | -1.21 Million USD | -1570.978% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 66.026% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -554.175% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -156.748% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -940.965% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -135390.118% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -27.846% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -248.807% |
| GB Sciences, Inc. | -1.36 Million USD | -1390.148% |
| Alpha Cognition Inc. | -13.77 Million USD | -47.329% |
| HST Global, Inc. | -146.21 Thousand USD | -13777.984% |
| CSL Limited | 2.64 Billion USD | 100.768% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -1056.333% |
| Halberd Corporation | -79.67 Thousand USD | -25366.891% |
| Enzolytics Inc. | -2.17 Million USD | -832.134% |
| Agentix Corp. | -1.37 Million USD | -1376.556% |
| Resverlogix Corp. | -3.61 Million USD | -462.078% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -539.805% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 93.123% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 20805.102% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 393.028% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -410.723% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -570.525% |
| AVAX Technologies, Inc. | -6.41 Million USD | -216.372% |
| Zenith Capital Corp. | -10.59 Million USD | -91.497% |
| Genscript Biotech Corporation | -95.47 Million USD | 78.748% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -87203.158% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -389.419% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -33471.799% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -911.962% |
| Kadimastem Ltd | -3.3 Million USD | -513.503% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1821.393% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -431.317% |
| BioStem Technologies, Inc. | -8.48 Million USD | -139.196% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -4497.287% |
| LadRx Corporation | 400.44 Thousand USD | 5167.138% |
| Cell Source, Inc. | -5.32 Million USD | -281.323% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2082.495% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2082.495% |
| NovAccess Global Inc. | -4.76 Million USD | -325.46% |
| Affymax, Inc. | -14.42 Million USD | -40.675% |
| Itoco Inc. | -1.86 Million USD | -985.664% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -356.744% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -1115.758% |
| Mobile Lads Corp. | -2.26 Million USD | -796.526% |
| CytoDyn Inc. | -49.84 Million USD | 59.289% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -25574.086% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -8794.607% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -2055.112% |
| SYBLEU INC | -180.3 Thousand USD | -11153.771% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -1158.172% |
| International Stem Cell Corporation | -131 Thousand USD | -15389.313% |
| Bioxytran, Inc. | -4.28 Million USD | -374.089% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -37287.603% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -701.938% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 57.79% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -859.839% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -2498.455% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -540.499% |
| Neutra Corp. | -233.46 Thousand USD | -8591.239% |
| PureTech Health plc | -65.69 Million USD | 69.114% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 4.587% |
| IXICO plc | -1.17 Million USD | -1622.496% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -104.402% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 64.482% |
| CSL Limited | 2.64 Billion USD | 100.768% |
| Cellectis S.A. | -103.17 Million USD | 80.333% |